CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced today that it will postpone
the release of its financial results and the conference call for the
fourth quarter and year-end 2010, both originally scheduled for February
22, 2011.
Kevin Green, vice president and chief accounting officer, said, "Due to
the complexities of the accounting and audit processes associated with
the Cerus’ acquisition of BioOne Corporation's assets, it has taken
longer than expected to finalize our year-end financial statements. We
will provide new dates and times for the earnings release and conference
call in a forthcoming news release."
ABOUT CERUS
Cerus Corporation is a biomedical products company focused on
commercializing the INTERCEPT Blood System to enhance blood safety. The
INTERCEPT system is designed to reduce the risk of
transfusion-transmitted diseases by inactivating a broad range of
pathogens such as viruses, bacteria and parasites that may be present in
donated blood. The nucleic acid targeting mechanism of action enables
INTERCEPT treatment to inactivate established transfusion threats, such
as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed
to inactivate emerging pathogens such as influenza, malaria and dengue.
Cerus currently markets and sells the INTERCEPT Blood System for both
platelets and plasma in Europe, Russia, the Middle East and selected
countries in other regions around the world. The INTERCEPT red blood
cell system is in clinical development. See http://www.cerus.com
for more information.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
Source: Cerus Corporation